GB201820626D0 - Conjugates - Google Patents

Conjugates

Info

Publication number
GB201820626D0
GB201820626D0 GBGB1820626.8A GB201820626A GB201820626D0 GB 201820626 D0 GB201820626 D0 GB 201820626D0 GB 201820626 A GB201820626 A GB 201820626A GB 201820626 D0 GB201820626 D0 GB 201820626D0
Authority
GB
United Kingdom
Prior art keywords
conjugates
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB1820626.8A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Canterbury
Original Assignee
University of Canterbury
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Canterbury filed Critical University of Canterbury
Priority to GBGB1820626.8A priority Critical patent/GB201820626D0/en
Publication of GB201820626D0 publication Critical patent/GB201820626D0/en
Priority to KR1020217022384A priority patent/KR20210106496A/ko
Priority to MX2021006802A priority patent/MX2021006802A/es
Priority to BR112021011860-8A priority patent/BR112021011860A2/pt
Priority to PCT/EP2019/086120 priority patent/WO2020127602A1/en
Priority to CA3123960A priority patent/CA3123960A1/en
Priority to EP19829152.8A priority patent/EP3897737A1/en
Priority to US17/416,284 priority patent/US20220054658A1/en
Priority to CN201980092600.6A priority patent/CN113474007A/zh
Priority to AU2019400788A priority patent/AU2019400788A1/en
Priority to JP2021535300A priority patent/JP2022514335A/ja
Priority to JP2025007027A priority patent/JP2025072404A/ja
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A61K31/37—Coumarins, e.g. psoralen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/545—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0045—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent agent being a peptide or protein used for imaging or diagnosis in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0052—Small organic molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/10—Anthelmintics
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pathology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
GBGB1820626.8A 2018-12-18 2018-12-18 Conjugates Ceased GB201820626D0 (en)

Priority Applications (12)

Application Number Priority Date Filing Date Title
GBGB1820626.8A GB201820626D0 (en) 2018-12-18 2018-12-18 Conjugates
JP2021535300A JP2022514335A (ja) 2018-12-18 2019-12-18 コンジュゲート
PCT/EP2019/086120 WO2020127602A1 (en) 2018-12-18 2019-12-18 Conjugates
MX2021006802A MX2021006802A (es) 2018-12-18 2019-12-18 Conjugados.
BR112021011860-8A BR112021011860A2 (pt) 2018-12-18 2019-12-18 Conjugados
KR1020217022384A KR20210106496A (ko) 2018-12-18 2019-12-18 컨쥬게이트
CA3123960A CA3123960A1 (en) 2018-12-18 2019-12-18 Conjugates
EP19829152.8A EP3897737A1 (en) 2018-12-18 2019-12-18 Conjugates
US17/416,284 US20220054658A1 (en) 2018-12-18 2019-12-18 Conjugates
CN201980092600.6A CN113474007A (zh) 2018-12-18 2019-12-18 缀合物
AU2019400788A AU2019400788A1 (en) 2018-12-18 2019-12-18 Conjugates
JP2025007027A JP2025072404A (ja) 2018-12-18 2025-01-17 コンジュゲート

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1820626.8A GB201820626D0 (en) 2018-12-18 2018-12-18 Conjugates

Publications (1)

Publication Number Publication Date
GB201820626D0 true GB201820626D0 (en) 2019-01-30

Family

ID=65147114

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB1820626.8A Ceased GB201820626D0 (en) 2018-12-18 2018-12-18 Conjugates

Country Status (11)

Country Link
US (1) US20220054658A1 (cg-RX-API-DMAC7.html)
EP (1) EP3897737A1 (cg-RX-API-DMAC7.html)
JP (2) JP2022514335A (cg-RX-API-DMAC7.html)
KR (1) KR20210106496A (cg-RX-API-DMAC7.html)
CN (1) CN113474007A (cg-RX-API-DMAC7.html)
AU (1) AU2019400788A1 (cg-RX-API-DMAC7.html)
BR (1) BR112021011860A2 (cg-RX-API-DMAC7.html)
CA (1) CA3123960A1 (cg-RX-API-DMAC7.html)
GB (1) GB201820626D0 (cg-RX-API-DMAC7.html)
MX (1) MX2021006802A (cg-RX-API-DMAC7.html)
WO (1) WO2020127602A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114685430B (zh) * 2022-03-18 2023-07-21 浙江大学 芬苯达唑类似物及制备方法和应用
WO2024049306A1 (en) * 2022-08-31 2024-03-07 Lopez Gonzalez Ricardo Chemical conjugates, compositions, and methods of preparation and use thereof
CN120987848B (zh) * 2025-07-10 2026-07-21 广州大学 一种含胍基结构单元的ε-己内酰胺化合物及其制备方法和应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0068485B1 (en) 1981-07-01 1987-11-11 Sanraku Incorporated Novel antibiotics and process for production thereof
EP2370411A4 (en) * 2008-12-05 2012-10-24 Univ Oregon Health & Science COMPOUNDS WITH ANTIPARASITIC OR ANTI-INFECTIOUS EFFECT
JP5852658B2 (ja) * 2010-09-24 2016-02-03 ザ リージェンツ オブ ザ ユニバーシティー オブ ミシガン デユビキチナーゼ阻害剤およびその使用方法
US20130345270A1 (en) * 2010-11-12 2013-12-26 Waake Forest University Health Sciences Methods of treating cancer and other disorders
EP2665738B1 (en) 2011-01-18 2018-09-26 The Royal Institution for the Advancement of Learning/McGill University Aminoglycosides for use in the treatment of bacterial infection
US9108942B1 (en) 2014-11-05 2015-08-18 Mahesh Kandula Compositions and methods for the treatment of moderate to severe pain
ES2907461T3 (es) * 2015-01-20 2022-04-25 Boehringer Ingelheim Animal Health Usa Inc Compuestos antihelmínticos, composiciones y procedimientos de uso de los mismos
WO2019060634A1 (en) 2017-09-20 2019-03-28 Thiogenesis Therapeutics, Inc. METHODS OF TREATING CYSTEAMINE SENSITIVE DISORDERS

Also Published As

Publication number Publication date
KR20210106496A (ko) 2021-08-30
JP2025072404A (ja) 2025-05-09
JP2022514335A (ja) 2022-02-10
US20220054658A1 (en) 2022-02-24
WO2020127602A1 (en) 2020-06-25
EP3897737A1 (en) 2021-10-27
CA3123960A1 (en) 2020-06-25
MX2021006802A (es) 2021-08-16
AU2019400788A1 (en) 2021-08-12
CN113474007A (zh) 2021-10-01
BR112021011860A2 (pt) 2021-09-08

Similar Documents

Publication Publication Date Title
ZA201904269B (en) Pyrrolobenzodiazepine-antibody conjugates
IL278990A (en) Captures of camptothecin
SG11202106606RA (en) Saponin conjugates
DK3793565T3 (en) Mcl-1-inhibitorer
IL277572A (en) IL-2 conjugates
CA185384S (en) Casque
PL3544636T3 (pl) Koniugaty pirolobenzodiazepina-przeciwciało
GB201702031D0 (en) Pyrrolobenzodiazepine-antibody conjugates
DK3773537T3 (en) Stat3-hæmmere
IL283801A (en) Insulin pens
CA184991S (en) Uroflowmeter
GB201820864D0 (en) Antibody-drug conjugates
DK3801538T3 (en) Tlr7-agonister
IL288681A (en) Pyrrolobenzodiazepine-antibody conjugates
GB201906997D0 (en) Conjugates
GB201802830D0 (en) Smartvalve
GB201811335D0 (en) Pyrrolobenzodiazepine-antibody conjugates
GB201811332D0 (en) Pyrroloobenzodiazepine-antibody conjugates
GB201900735D0 (en) Conjugates
CA187782S (en) Pompon-maker
GB201721290D0 (en) Conjugates
GB201719906D0 (en) Pyrrolobenzodiazepine-antibody conjugates
GB201719393D0 (en) Pyrrolobenzodiazepine-antibody conjugates
GB201719398D0 (en) Pyrrolobenzodiazepine-antibody conjugates
GB201719391D0 (en) Pyrrolobenzodiazepine-antibody conjugates

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)